Clinical Trial

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated November 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-23.
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06659042
Lead Sponsor Shanghai Chest Hospital
Conditions Lung Cancer, Non-Small Cell
Enrollment 32 participants
Start Date 2024-11-20
Primary Completion 2025-11-20 (estimated)
Study Completion 2027-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-05-18